Ghrelin administration did not significantly alter glucose or insulin levels in obese women.
According to recent research published in the journal Diabetes Obesity & Metabolism, “Ghrelin is a 28-amino-acid peptide, predominantly produced by the stomach. There are several studies that suggest the importance of ghrelin in obesity. However, the pancreatic endocrine response to ghrelin in obesity is unclear at present. The aim of this study was to clarify whether ghrelin administration influences glucose and insulin levels in obese patients.”
“Six obese female patients (31?”Glucose (mean peak, mmol/L) level after placebo administration was 4.9?of these abnormalities in the type 2 diabetic group were reversed by rosiglitazone treatment.”
The researchers concluded, “These studies have shown that elevated malonyl-CoA levels and decreased fatty acid oxidation are key abnormalities in insulin-resistant muscle, and, in type 2 diabetic patients, thiazolidinedione treatment can reverse these abnormalities.”
Bandyopadhyay and colleagues published the results of their research in Diabetes (Increased malonyl-CoA levels in muscle from obese and type 2 diabetic subjects lead to decreased fatty acid oxidation and increased lipogenesis; thiazolidinedione treatment reverses these defects. Diabetes, 2006;55(8):2277-2285).
For additional information, contact J.M. Olefsky, University of California, Dept. of Medical, Division Endocrinol & Metab, Mail Code 0673, 9500 Gilman Dr., La Jolla, CA 92093, USA.
The publisher of the journal Diabetes can be contacted at: American Diabetes Association, 1701 N Beauregard St., Alexandria, VA 22311-1717, USA.
